Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIORESAL vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
FDA-approved: Intrathecal: severe spasticity of cerebral or spinal origin; Oral: spasticity in multiple sclerosis, spinal cord injury. Off-label: Trigeminal neuralgia, essential tremor, chronic hiccups, alcohol withdrawal, stiff-person syndrome, dystonia, gastroesophageal reflux disease, epilepsy, autism, cluster headaches, intractable hiccups, cocaine dependence, Huntington disease, Tourette syndrome, tardive dyskinesia, periodic limb movement disorder, myoclonus, apraxia of eyelid opening, hemifacial spasm, nystagmus, tic disorders, generalized anxiety disorder, insomnia, and chronic hiccup.
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Hepatic metabolism via deamination (minor pathway); primarily excreted unchanged in urine (70-80% as parent drug, 15% as metabolites).
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
~30%; primarily bound to albumin.
30-35% bound to albumin.
0.5-1.0 L/kg; indicates moderate tissue distribution, with higher CNS penetration when administered intrathecally.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: 70-80% (first-pass effect minimal); intrathecal: nearly 100% due to direct CSF administration.
Oral: 70-85% with high variability; intrathecal: 100%.
GFR >60 m L/min: no adjustment; GFR 30-60: reduce dose by 25-50%; GFR <30: avoid or reduce by 75%; hemodialysis: supplement dose after dialysis.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Oral: 2.5 mg 4 times daily initially, increase by 2.5-5 mg every 3 days to max 40 mg/day (2-7 years) or 60 mg/day (8-15 years). Intrathecal: test dose 25-50 mcg; maintenance 100-1000 mcg/day.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Start at 5 mg twice daily; increase slowly due to increased CNS sensitivity; monitor for sedation and confusion.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
Abrupt discontinuation of intrathecal baclofen may result in life-threatening withdrawal reactions (high fever, altered mental status, severe spasticity, rhabdomyolysis, autonomic dysfunction).
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Abrupt discontinuation: may cause withdrawal symptoms (hallucinations, seizures, hyperthermia, rebound spasticity). Sedation: may impair ability to drive or operate machinery. Renal impairment: dose adjustment required. Avoid concomitant use with CNS depressants (alcohol, benzodiazepines). Caution in stroke patients, respiratory depression, psychiatric disorders, epilepsy, and pregnancy.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Absolute: Hypersensitivity to baclofen or any component; concomitant use of oral baclofen and intrathecal baclofen; intrathecal use contraindicated in patients with IV access device infection, spinal canal obstruction, or bleeding diathesis. Relative: Renal impairment, hepatic impairment, respiratory insufficiency, seizure disorder, history of autonomic dysreflexia, pregnancy, and lactation.
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
No specific food interactions, but take with or without food consistently to avoid variable absorption.
No specific food interactions. Avoid alcohol due to additive CNS depression.
First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia, and withdrawal symptoms (irritability, tremors) in neonates. Use only if benefit outweighs risk.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Lioresal (baclofen) is excreted into human breast milk in low concentrations; M/P ratio is approximately 0.4-0.7. No adverse effects reported in nursing infants. Caution advised, especially in preterm infants or those with renal impairment.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
Increased clearance and volume of distribution during pregnancy may require dose adjustments. Dose should be titrated to lowest effective dose, with close monitoring for efficacy and toxicity. No specific dose adjustment guidelines; individualize based on clinical response.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
Titrate slowly to avoid sedation and muscle weakness; monitor for withdrawal signs after abrupt discontinuation (e.g., spasticity rebound, hyperpyrexia, seizures). Intrathecal pump requires specialist management.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Take exactly as prescribed; do not suddenly stop taking this medication.,Avoid alcohol and other CNS depressants.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Report any unusual muscle weakness, confusion, or difficulty breathing.,Keep medication in original container away from moisture and heat.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIORESAL vs BACLOFEN, answered by our medical review team.
LIORESAL is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIORESAL and BACLOFEN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIORESAL is: Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIORESAL and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIORESAL is classified as Category C. First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.